Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 20, 2017— The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1), Representing a 40% Reduction in Risk of Progression or Death —
NEWTON, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported a successful outcome from the Phase 2 portion...
-
Sep 12, 2017— Michael Falvey, Formerly an Executive at Millennium Pharmaceuticals, Seven Bridges Genomics, Ahura Scientific, and Aspect Medical Systems, Brings 35 Years of Financial and Operational Experience at High Growth Companies —
NEWTON, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Michael Falvey as...
-
Sep 8, 2017Top-line Phase 1 Selinexor Data in Combination with Chemotherapy Show Encouraging Early Efficacy in Patients with Ovarian and Endometrial Cancers
NEWTON, Mass., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the...
-
Aug 30, 2017
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Aug 30, 2017
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the...
-
Aug 8, 2017− Pivotal Phase 3 BOSTON Study Underway -
NEWTON, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2017...
-
Aug 1, 2017
NEWTON, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2017...
-
Jun 23, 2017Objective Response Rate Increases to 33.3% Overall and is 35% in Patients with "Double- or Triple-Hit" DLBCL
NEWTON, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported updated clinical data from the ongoing Phase 2b...
-
Jun 7, 2017
NEWTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in its pivotal...
-
May 31, 2017
NEWTON, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive...